IRF4 at the crossroads of effector T-cell fate decision

被引:173
|
作者
Huber, Magdalena [1 ]
Lohoff, Michael [1 ]
机构
[1] Univ Marburg, Inst Med Microbiol & Hosp Hyg, D-35032 Marburg, Germany
关键词
CD4(+) T cells; CD8(+) T cells; Interferon regulatory factor 4; T-cell differentiation; T-cell subsets; REGULATORY FACTOR 4; TRANSCRIPTION FACTOR IRF4; FACTOR BATF CONTROLS; GERMINAL CENTER B; DENDRITIC CELLS; GENE-EXPRESSION; TC9; CELLS; DIFFERENTIATION; FACTOR-4; RESPONSES;
D O I
10.1002/eji.201344279
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interferon regulatory factor 4 (IRF4) is a transcription factor that is expressed in hematopoietic cells and plays pivotal roles in the immune response. Originally described as a lymphocyte-specific nuclear factor, IRF4 promotes differentiation of naive CD4(+) T cells into T helper 2 (Th2), Th9, Th17, or T follicular helper (Tfh) cells and is required for the function of effector regulatory T (eTreg) cells. Moreover, IRF4 is essential for the sustained differentiation of cytotoxic effector CD8(+) T cells, for CD8(+) T-cell memory formation, and for differentiation of naive CD8(+) T cells into IL-9-producing (Tc9) and IL-17-producing (Tc17) CD8(+) T-cell subsets. In this review, we focus on recent findings on the role of IRF4 during the development of CD4(+) and CD8(+) T-cell subsets and the impact of IRF4 on T-cell-mediated immune responses in vivo.
引用
收藏
页码:1886 / 1895
页数:10
相关论文
共 50 条
  • [21] Impact of IRF4/MUM1 Expression on Adult T-Cell Leukemia/Lymphoma and Treatment Outcome
    Castillo, Luis E. Malpica
    Campuzano-Zuluaga, German
    Toomey, Ngoc L.
    Pimentel, Agustin
    Chapman-Fredricks, Jennifer Rose
    Ramos, Juan Carlos
    BLOOD, 2017, 130
  • [22] IRF4 Translocations Are Specific for Cutaneous Anaplastic Large Cell Lymphoma in Skin Biopsies Involved by T-Cell Lymphoproliferative Disorders
    Wada, D.
    Law, M. E.
    de Souza, A.
    Weenig, R.
    Comfere, N.
    Macon, W. R.
    Erickson, L. A.
    Dogan, A.
    Feldman, A. L.
    LABORATORY INVESTIGATION, 2009, 89 : 289A - 289A
  • [23] Suppression of Inflammasome Activation by IRF8 and IRF4 in cDCs is Critical for T cell Priming
    McDaniel, Margaret
    Pasare, Chandrashekhar
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [24] Suppression of Inflammasome Activation by IRF8 and IRF4 in cDCs Is Critical for T Cell Priming
    McDaniel, Margaret M.
    Kottyan, Leah C.
    Singh, Harinder
    Pasare, Chandrashekhar
    CELL REPORTS, 2020, 31 (05):
  • [25] The IRF4 Gene Regulatory Module Functions as a Read-Write Integrator to Dynamically Coordinate T Helper Cell Fate
    Krishnamoorthy, Veena
    Kannanganat, Sunil
    Maienschein-Cline, Mark
    Cook, Sarah L.
    Chen, Jianjun
    Bahroos, Neil
    Sievert, Evelyn
    Corse, Emily
    Chong, Anita
    Sciammas, Roger
    IMMUNITY, 2017, 47 (03) : 481 - +
  • [26] IRF4 controls a core regulatory circuit of T cell dysfunction in transplantation
    Wu, Jie
    Shi, Xiaomin
    Xiao, Xiang
    Minze, Laurie
    Wang, Jin
    Ghobrial, Rafik M.
    Xia, Jiahong
    Sciammas, Roger
    Li, Xian C.
    Chen, Wenhao
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [27] The IRF4 gene regulatory module functions as a read-write integrator to dynamically control T helper cell fate
    Sciammas, Roger
    Krishnamoorthy, Veena
    Kannanganat, Sunil
    Maienschein-Cline, Mark
    Cook, Sarah
    Chen, Jianjun
    Bahroos, Neil
    Corse, Emily
    Chong, Anita S. F.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [28] mTOR signaling at the crossroads of environmental signals and T-cell fate decisions
    Huang, Hongling
    Long, Lingyun
    Zhou, Peipei
    Chapman, Nicole M.
    Chi, Hongbo
    IMMUNOLOGICAL REVIEWS, 2020, 295 (01) : 15 - 38
  • [29] Critical Functions of IRF4 in B and T Lymphocytes
    Hagman, James
    JOURNAL OF IMMUNOLOGY, 2017, 199 (11): : 3715 - 3716
  • [30] IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma
    Heo, Mi Hwa
    Park, Ha Young
    Ko, Young Hyeh
    Kim, Won Seog
    Kim, Seok Jin
    JOURNAL OF CANCER, 2017, 8 (06): : 1018 - 1024